The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Runners jog past an AstraZeneca site in Macclesfield, central England April 28, 2014.
Runners jog past an AstraZeneca site in Macclesfield, central England April 28, 2014.
(Darren Staples/Reuters)

Investors, time to move into health care stocks

The global health care sector is on fire and as much as I’ve written on the sector lately, the ocean of cash changing hands through merger and acquisition activity lately suggests I haven’t done enough.

On Monday, Pfizer Inc. announced it would renew efforts to acquire U.K-based AstraZeneca PLC in a deal Reuters projected could reach $100-billion (U.S.). The news comes hot on the heels of an announced bid by Valeant Pharmaceuticals International Inc. worth almost $50-billion for Allergan Inc.; a $36-billion asset swap between GlaxoSmithKline PLC, Novartis AG and Eli Lilly and Co.; and orthopedic giant Zimmer Holdings Inc.’s $13-billion bid for rival Biomet Inc.